×
Glucose Health EBIT 2014-2019 | GLUC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Glucose Health ebit from 2014 to 2019. Ebit can be defined as earnings before interest and taxes.
View More
Glucose Health EBIT 2014-2019 | GLUC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Glucose Health ebit from 2014 to 2019. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Abbott Laboratories (ABT)
$206.3B
Stryker (SYK)
$148B
Boston Scientific (BSX)
$133.7B
EssilorLuxottica (ESLOY)
$111.2B
Medtronic (MDT)
$110.6B
Haleon (HLN)
$44B
Lonza Group Ag (LZAGY)
$42.2B
GE HealthCare Technologies (GEHC)
$37.9B
ResMed (RMD)
$36.6B
Terumo (TRUMY)
$30.3B
Koninklijke Philips (PHG)
$25.5B
Zimmer Biomet Holdings (ZBH)
$22.3B
Insulet (PODD)
$18.7B
Baxter (BAX)
$17B
Smith & Nephew SNATS (SNN)
$11.2B
BellRing Brands (BRBR)
$9.9B
Bio-Rad Laboratories (BIO)
$9.5B
Demant (WILYY)
$8.3B
Lantheus Holdings (LNTH)
$6.3B
TG Therapeutics (TGTX)
$5.4B
Haemonetics (HAE)
$4.4B
Prestige Consumer Healthcare (PBH)
$4.2B
Perrigo (PRGO)
$3.9B
ICU Medical (ICUI)
$3.9B
Envista Holdings (NVST)
$3.8B
Agios Pharmaceuticals (AGIO)
$3.3B
Neogen (NEOG)
$3.1B
Shandong Weigao Medical Polymer (SHWGF)
$3B
GN Store Nord (GNNDY)
$2.9B
QuidelOrtho (QDEL)
$2.8B